Mode
Text Size
Log in / Sign up

Chronic rhinosinusitis

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for chronic rhinosinusitis

28 trials tracked for chronic rhinosinusitis: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 98 citations.

28Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 6 Phase 3 8 Phase 2 5 Other / NA 9
  1. Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 98 cited
  2. Phase 3 A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Completed · 97 cited
  3. Phase 4 The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis Completed · 73 cited
  4. Phase 3 An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps Completed · 21 cited
  5. Phase 4 Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis Completed
  6. Phase 4 The Use of Antibiotic Sinonasal Rinse After Sinus Surgery Completed
Show 22 more trials
  1. Phase 4 Erenumab for Idiosyncratic Facial Pain Completed
  2. Phase 4 Treatment of Acute Sinusitis Completed
  3. Phase 4 Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel Completed
  4. Phase 3 Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations Completed
  5. Phase 3 Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis Completed
  6. Phase 3 Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps Completed
  7. Phase 3 Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps Completed
  8. Phase 3 Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis Completed
  9. Phase 2 Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis Completed
  10. Phase 2 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi Completed
  11. Phase 2 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis Completed
  12. Phase 2 The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis Completed
  13. Phase 2 Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Completed
  14. N/A Healthcare Utilization and Outcomes of FinESS Treatment in the Office Completed
  15. N/A Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis After Endoscopic Sinus Surgery Completed
  16. N/A NuVent™ Revision Study Completed
  17. N/A Impact of Symbiofilm On Nasal Microbiota Completed
  18. N/A Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease Completed
  19. N/A Point-of-Care Computed Tomography (CT) Chronic Rhinosinusitis Study Completed
  20. N/A Microcurrent Device (TIVIC Health) Completed
  21. N/A NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis Completed
  22. N/A Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP) Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Chronic rhinosinusitis: what the trials found

Omalizumab (anti-IgE) significantly improves nasal polyp scores, nasal congestion, and sense of smell in patients with chronic rhinosinusitis with nasal polyps. In two phase 3 trials (N=127 and N=138), omalizumab reduced nasal polyp score (NPS) by -0.90 and -1.08 vs placebo (p=0.014 and p<0.0001, respectively) and improved nasal congestion score (NCS) by -0.70 and -0.89 (p=0.0017 and p=0.0004) 78. A third phase 3 trial (N=249) confirmed these benefits, showing consistent reductions in NPS and NCS across multiple dose groups 9.

OPN-375, a novel intranasal formulation, improved composite symptom scores (nasal congestion, facial pain/pressure, nasal discharge) and sinonasal opacification on imaging in two phase 3 trials. In one trial (N=223), the composite symptom score improved by -1.54 and -1.74 vs -0.81 with placebo at week 4, and the average percent of opacified volume (APOV) decreased by -7.00 and -5.14 vs +1.19 with placebo at week 24 10. A second trial (N=332) showed similar trends, though the higher dose group had a smaller symptom improvement (-0.62 vs -1.58 for placebo) 11.

Budesonide, mupirocin, and AdvaCoat sinus gel have been studied in phase 4 trials for chronic rhinosinusitis, but specific outcome data are not available from the provided trials 136. Acetaminophen showed no significant difference in SNOT-16 scores at day 3 (p=0.83) 5. A probiotic containing L. rhamnosus R0011 did not significantly reduce SNOT-20 scores (p=0.23) or antibiotic use 4. Oral levofloxacin did not significantly improve RSDI (p=0.505) or POSE scores (p=0.390) in a small phase 3 trial (N=33) 13. BNO 1016 improved major symptom scores and SNOT-20 scores in a phase 3 trial (N=386) 14. Acetylcysteine showed no clear benefit on major symptom scores in a large phase 3 trial (N=944) 12. Erenumab did not significantly reduce mid-facial pain or SNOT-22 scores (p=0.96 and p=0.19) 2.

Recent results — preliminary, needs further review

  • Etokimab (anti-IL-33) did not significantly improve nasal polyp score (p=0.2364) or SNOT-22 (p=0.1330) at week 16 in a phase 2 trial (N=105) 17.
  • Silver colloid showed variable changes in SNOT-22 and endoscopic scores in a small phase 2 trial (N=22), but no p-values are reported 18.
  • A microcurrent TENS device showed small changes in pain VAS scores after repeated use in a phase N/A trial (N=60), but no p-values are provided 20.
  • Healsea® Chronic nasal spray did not significantly alter sinonasal microbiota alpha-diversity (p=0.908) but improved SNOT-22 scores by -17.5 points in a small trial (N=12) 21.
  • An unlabeled trial (N=294) reported a -4.37 change in investigator-assessed symptom severity, but no intervention is specified 22.

For the clinician treating this condition

  • Omalizumab is effective for chronic rhinosinusitis with nasal polyps, improving polyp scores, congestion, and smell.
  • OPN-375 improves composite symptoms and sinus opacification, though results vary by dose.
  • Several other interventions (e.g., acetaminophen, probiotics, levofloxacin, acetylcysteine) lack significant benefit in available trials.

AI synthesis of 19 cited trials, updated Jun 28, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about chronic rhinosinusitis

Are there specific genes linked to chronic rhinosinusitis and nasal polyps?

Yes, several genes and genetic pathways are linked to chronic rhinosinusitis with nasal polyps, including FOXP3, STAT1, and miRNAs like miR-130a-3p and miR-196b-5p.

Full answer →
Can anti-IL-5 biologics be used to treat severe chronic rhinosinusitis?

Yes, anti-IL-5 biologics (mepolizumab, reslizumab, benralizumab) are approved for severe chronic rhinosinusitis with nasal polyps and reduce symptoms and need for surgery.

Full answer →
Do nasal irrigation and steroid implants improve outcomes for chronic rhinosinusitis?

Yes, both nasal irrigation and steroid implants improve symptoms and reduce recurrence in chronic rhinosinusitis, with steroid implants showing rapid, durable effects.

Full answer →